Physician profile
Jorge Black
NPI 1518957471
$868.74
in general payments reported to CMS, 2019-2025
12 companies · $15.79 in 2025
The $15.79 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $151 · 2021: $360 · 2022: $15.35 · 2023: $72.13 · 2024: $46.99 · 2025: $15.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $134.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $218.71 | 2019-2023 | Bexsero, Pediarix |
| Takeda Pharmaceuticals U.S.A., INC. | $191.84 | 2020-2021 | |
| Corium, LLC | $78.35 | 2021 | |
| Cranial Technologies, INC | $72.21 | 2019-2025 | Doc Band |
| Sanofi Pasteur INC. | $71.63 | 2019-2023 | |
| Covidien LP | $68.25 | 2019 | |
| Pfizer INC. | $45.51 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $37.83 | 2020-2021 | |
| Genentech USA, INC. | $27.35 | 2019-2020 | |
| Shire North American Group INC | $23.13 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.20 | 2024 | Flumist Quadrivalent |
| Cumberland Pharmaceuticals, INC. | $14.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.